Top Markets
#1 Siren Siren +40.14%
#2 RedStone RedStone +24.77%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#4 Perle Perle +16.73%
#5 Ocean Protocol Ocean Protocol +15.17%
#6 KUB Coin KUB Coin +14.22%
#7 Verus Coin Verus Coin +13.72%
#8 Cysic Cysic +10.99%
#9 Quack AI Quack AI +10.58%
#10 Arowana Arowana +10.51%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Rank in Stocks #32096
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Share Price
$0.21483059
Last synced: 2024-05-07
Market Cap
$11.13M
Change (1 day)
0.34%
Change (1 year)
0.00%
Country
CA
Trade Antibe Therapeutics Inc. (ATE)

Category

Healthcare
Revenue for Antibe Therapeutics Inc. (ATE)
Revenue in Aug 2026 TTM: 0
According to Antibe Therapeutics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Antibe Therapeutics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 $46.59B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 $25.84B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 $35.48B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 $21.00B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 $6.51B -
US